Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-Mirc415
- Development stage
- Unknown
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-Mirc415 is a radiopharmaceutical diagnostic agent consisting of a nanobody (single-domain antibody fragment) labeled with the positron-emitting radionuclide gallium-68. It targets programmed death ligand 2 (PD-L2), an immunoinhibitory molecule expressed in various tumors and immune cells. The agent is designed for use in positron emission tomography (PET) imaging to visualize PD-L2 expression, which may have applications in oncology, particularly for patient selection and monitoring response to immunotherapies targeting the PD-1/PD-L1/PD-L2 axis. As of recent reports, it has been evaluated in phase I clinical trials for its diagnostic potential[3].
- Other names
- 68Ga-Mirc415
02
Targets
PDCD1LG2 (Programmed cell death 1 ligand 2)
Beyond the preview
Go deeper on 68Ga-Mirc415.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-Mirc415.